Traws Pharma, Inc (TRAW) Fair Value & Analysis
Healthcare · US · Market cap $13.5M
Traws Pharma, Inc
TRAW · US
Fair value as of: Jul 21, 2026
From 8 valuation models · updated today
Share price −28.2% over the past month.
Price vs Fair Value (12 months)
12‑month range $0.6107 – $3.13 · fair‑value band $0.5165 – $0.8951 · the $0.6107 price screens below the $0.6888 fair value. As of Jul 21, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Traws Pharma, Inc (TRAW) currently trades at $0.6107, while our model-based Fair Value estimate is $0.6888, implying the stock looks roughly 12.8% undervalued today. We read business quality at 37/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Trailing-twelve-month revenue stands at $2.7M. The balance sheet holds a net cash position of $3.8M. Fundamentals as of Jul 21, 2026
Our scenario range runs from $0.5165 (bear case) to $0.8951 (bull case); at $0.6107, the current price sits within that range. For context, the median of 10 Healthcare peers we cover trades at -27% fair-value upside, at 13%, TRAW screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 21, 2026. TTM = trailing twelve months.
About the company
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., Knight Therapeutics Inc., Specialised Therapeutics Asia Pte. Ltd., and Temple University. The company was formerly known as …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Traws Pharma, Inc reported revenue of $2.8M in FY2025 versus $226K in FY2021, a compound +87.4%/yr. Reported net income was $9.2M in FY2025.
Is TRAW fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | 7,746 MXN | 5,617 MXN | -27% |
| Regeneron Pharmaceuticals, Inc REGN34 | R$52.30 | R$9.67 | -82% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $935.38 | $382.64 | -59% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
| CSL Limited CSL | A$116.32 | A$126.60 | +9% |
| Celltrion, Inc 068270 | 168,500 KRW | 76,943 KRW | -54% |
| BioNTech SE B1NT34 | R$28.41 | R$23.67 | -17% |
| WuXi Biologics (Cayman) Inc 2269 | HK$29.70 | HK$26.76 | -10% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Traws Pharma, Inc (TRAW) undervalued?
What is the fair value of TRAW?
What is the quality score of TRAW?
What is the revenue of Traws Pharma, Inc (TRAW)?
What is the net profit margin of TRAW?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Traws Pharma, Inc analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.